(126 days)
HDS HI 1.54™ rigid gas permeable contact lenses are indicated for daily wear as recommended by the eye care practitioner.
HDS HI 1.54™ rigid gas permeable spherical, aspheric and bifocal contact lenses are indicated for the correction of refractive ametropia in not-aphakic persons with non-diseased eyes that are nearsighted (myopic), farsighted (hyperopic), and may exhibit corneal astigmatism up to 4.00 diopters that does not interfere with visual acuity. HDS HI 1.54™ toric contact lenses are indicated to correct astigmatism of up to 6.00 diopters.
HDS HI 1.54™ bifocal lenses are indicated to treat presbyopia up to +4.00 D add power.
HDS HI 1.54™ contact lenses are indicated for management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty, radial keratotomy, or LASIK surgery, in otherwise non-diseased eyes.
HDS HI 1.54 (pahrifocon A) rigid gas permeable contact lenses for daily wear are available as lathe cut contact lenses with spherical, aspheric, bifocal or toric anterior and/or posterior, or, bitoric surfaces in clear and tinted versions. The posterior curve is selected so as to properly fit an individual eye and the anterior curve is selected to provide the necessary optical power to correct refractive error. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.
The HDS HI 1.54 rigid gas permeable contact lens material is a thermoset copolymer derived from acrylate, silicone acrylate, and fluorosilicone acrylate monomers, dimers and oligomers.
The HDS HI 1.54 rigid gas permeable tinted lenses offer a handling aid for locating the lens and may be plasma treated.
Here's a breakdown of the acceptance criteria and the study details for the Paragon HDS HI 1.54 rigid gas permeable contact lens, based on the provided 510(k) summary:
Acceptance Criteria and Device Performance
The acceptance criteria are not explicitly stated as distinct pass/fail thresholds in a formal table; instead, the submission focuses on demonstrating "substantial equivalence" to the predicate device (FluoroPerm 30) through comparative performance data and clinical outcomes. The device performance is generally presented by comparing the HDS HI 1.54 to the predicate or demonstrating acceptable clinical observations.
Given the information, I've constructed a table highlighting key properties and clinical outcomes where performance comparison implicitly serves as the acceptance criterion (i.e., being comparable to or better than the predicate, or within expected clinical ranges).
| Property/Clinical Outcome | Acceptance Criteria (Implied) | Reported HDS HI 1.54 Performance (Un-irradiated) | Reported FluoroPerm 30 Performance (Predicate) |
|---|---|---|---|
| Material Properties | |||
| Specific Gravity | Comparable to predicate | 1.12 | 1.14 |
| Refractive Index | Comparable to predicate | 1.54 | 1.466 |
| % Light Transmittance | Comparable to predicate (for blue tinted material) | 93 | 94 |
| % Water Content | Comparable to predicate | 1 | <1 |
| Oxygen Permeability (Dk) | Comparable to predicate | 22 | 30 |
| Hardness (Shore D) | Comparable to predicate | 84 | 84 |
| Modulus, kgf/cm² | Comparable to predicate | 16,990 | 16,660 |
| Flexure Stress, kgf/cm² | Comparable to predicate | 559 | 505 |
| Flexure Strain, % | Comparable to predicate | 4 | 4 |
| Toughness, gf-mm | Comparable to predicate | 429 | 440 |
| Preservative Uptake (CDG, PAPBG) | Comparable to predicate | CDG 0.35, PAPBG 0.01 | CDG 0.80, PAPBG 0.01 |
| Preservative Release (CDG, PAPBG) | Comparable to predicate | CDG 0.02, PAPBG 0.01 | CDG 0.05, PAPBG 0.01 |
| Soxhlet Extractables (Hexane / Water) | Comparable to predicate | 3.87 / 0.66 | 3.45 / 0.10 |
| Residuals (Acetonitrile, VC-VP) | Acceptable levels (comparison not directly stated for predicate) | 2.67-0.72 | - |
| Wetting Angle (Receding/Sessile Drop) | Comparable to predicate | 44/77 | 13/68 |
| Clinical Outcomes | |||
| Adverse Events | None reported | None reported | N/A (historical control) |
| Complications (Slit Lamp Grade 3) | Resolution without complication | Few, resolved without complication | N/A (historical control) |
| Slit Lamp Findings (Grade 1/Trace) | Within expected values | Primarily Grade 1 (trace) | N/A (historical control) |
| Discomfort | Comparable frequency to control | 13.7% of Completed Test eye visits | 12.3% of Completed Control Eye visits |
| Lens Comfort Rating | "Very good" (average ~4.0 on a scale) and comparable to control | 4.04 (very good) | 4.07 (very good) |
| Keratometry Changes | Within 1.00 diopter for high percentage of eyes | 93.1% within 1.00 D | 96.4% within 1.00 D |
| Manifest Refraction Changes | Within 1.00 diopter for high percentage of eyes | 97.9% within 1.00 D | 98.2% within 1.00 D |
| Decrease in CL Visual Acuity | Low incidence, with identified reasons (e.g., measurement error, lens switched) | 1 eye had >0.20 logMAR decrease (measurement error) | 1 eye had >0.20 logMAR decrease (lenses switched) |
| Lens Wearing Time | Stable over 13 hours/day, comparable to control | Over 13 hours/day | Over 13 hours/day |
| Lens Replacements | Reasons predominantly for deposits/parameter, discomfort comparable to control | 49 replacements (deposits, parameter change, discomfort) | N/A (historical control, reasons for discontinuation specified) |
| Overall Equivalence | Substantial equivalence to predicate demonstrated | Achieved | N/A |
Study Details
-
Sample Size used for the test set and the data provenance:
- Sample Size: 76 subjects (152 eyes) were enrolled. 64 subjects (84.2%) completed the study.
- Data Provenance: The study was a multi-site, randomized, double-masked clinical study. The country of origin is not explicitly stated, but the submission is to the US FDA, implying that the study was likely conducted in the US or under ICH GCP guidelines applicable to US submissions. The study was prospective as it involved enrolling subjects and following them with the investigational device.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- This was a clinical study involving patients wearing contact lenses, with outcomes measured by eye care practitioners. The text does not specify the number of individual "experts" used to establish ground truth in the sense of adjudication for, for example, image interpretation. However, the study was conducted by clinicians/investigators at multiple sites, presumed to be qualified eye care practitioners. Their qualifications (e.g., ophthalmologists, optometrists, years of experience) are not detailed in this summary.
-
Adjudication method for the test set:
- The document describes a "multisite, randomized, double masked clinical study." This suggests that the investigators assessing patient outcomes were masked to whether the patient was using the investigational or control lens where possible, reducing bias in assessment. There is no mention of a formal adjudication panel (e.g., 2+1, 3+1) specifically for reviewing clinical outcomes or discrete "ground truth" events. Clinical findings (e.g., slit lamp evaluation, comfort ratings, visual acuity) would have been recorded by the examining clinicians.
-
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This study is for a physical medical device (contact lens) and does not involve AI or human readers interpreting cases.
-
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- No. This device is a contact lens and does not involve an algorithm.
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- For this contact lens study, the "ground truth" for evaluating performance and safety was derived from clinical outcomes data directly observed and recorded by eye care practitioners during patient visits, supplemented by patient-reported comfort and wearing time. This includes:
- Slit lamp findings (e.g., injection, staining)
- Keratometry changes
- Manifest refraction changes
- Visual acuity measurements
- Patient comfort ratings
- Wearing time
- Reports of adverse events and complications.
- For this contact lens study, the "ground truth" for evaluating performance and safety was derived from clinical outcomes data directly observed and recorded by eye care practitioners during patient visits, supplemented by patient-reported comfort and wearing time. This includes:
-
The sample size for the training set:
- This is a contact lens, not an AI/ML device, so there is no "training set" in the context of machine learning. The non-clinical tests involved laboratory characterization of the material.
-
How the ground truth for the training set was established:
- Not applicable as there is no training set for an AI/ML algorithm. Material properties were established through standard laboratory testing methods (e.g., ISO, ANSI methods for Dk, transmittance, wetting angle, hardness, modulus, etc., and USP/ISO methods for biological reactivity, toxicity).
{0}------------------------------------------------
JAN 2 7 2009
510(k) Summary
Date of Summary
January 19, 2009
Submitter
な
| Company Name: | |
|---|---|
| Address: | |
| Phone: | |
| Fax: | |
| Registration: |
Paragon Vision Sciences 945 East Impala Ave., Mesa, AZ 85204 480-892-7602 480-892-3226 Owner Operator # 9024618
Manufacturer Information
| Company Name: | |
|---|---|
| Address: | |
| Phone: | |
| Fax: | |
| Registration: |
Paragon Vision Sciences 945 East Impala Ave., Mesa, AZ 85204 480-892-7602 480-892-3226 Site Registration #2020433
Official Correspondent
| Name: | |
|---|---|
| Address: | |
| Address: | |
| Phone: | |
| Fax: |
William E. Meyers, Ph.D. % Paragon Vision Sciences 945 East Impala Ave., Mesa, AZ 85204 480-507-7606 480-892-3226
Device Name
HDS HI 1.54 Trade Name pahrifocon A USAN Name
Classification & Ophthalmic Devices Branch
| Common Name: | Contact lens |
|---|---|
| Product Code: | HQD |
| Classification Name: | Rigid gas permeable contact lens for daily wear |
| Classification Panel: | Ophthalmic |
| Reference: | 21 CFR 886.5916; rigid gas permeable contact lens,Class II - daily wear contact lens |
{1}------------------------------------------------
Marketed device to which equivalence is claimed is FluoroPerm 30 (paflufocon c).
HDS HI 1.54 (pahrifocon A) rigid gas permeable contact lenses for daily wear are available as lathe cut contact lenses with spherical, aspheric, bifocal or toric anterior and/or posterior, or, bitoric surfaces in clear and tinted versions. The posterior curve is selected so as to properly fit an individual eye and the anterior curve is selected to provide the necessary optical power to correct refractive error. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.
The HDS HI 1.54 rigid gas permeable contact lens material is a thermoset copolymer derived from acrylate, silicone acrylate, and fluorosilicone acrylate monomers, dimers and oligomers.
The HDS HI 1.54 rigid gas permeable tinted lenses offer a handling aid for locating the lens and may be plasma treated.
| Refractive Index | 1.54 |
|---|---|
| Luminous Transmittance+ (Clear) | 97% |
| Luminous Transmittance (Blue) | 93% |
| Luminous Transmittance (Green) | 94 |
| Wetting Angle (Receding Angle)++ | 44° |
| Wetting Angle (Sessile Drop)+++ | 77° |
| Specific Gravity | 1.12 |
| Hardness (Shore D) | 84 |
| Water Content | <1% |
| Oxygen Permeability* | 22x10-11 Dk at 35° C |
- Determination of the Spectral and Luminous Transmittance, ISO 8599:1994
Adapted from: A New Method for Wetting Angle Messurement; Madigan, et al., International Eyecare, 01/1998, vol. 2, go. 1, p. 45
*** Sessile Drop Technique per ANSI Z80.20. 8.11
*(cm3/sec) (mL O2) / (mL x mm Hg) ISO/ANSI Method, ISO 9913-1
Indications for use
HDS HI 1.54™ rigid gas permeable contact lenses are indicated for daily wear as recommended by the eye care practitioner.
HDS HI 1.54™ rigid gas permeable spherical, aspheric and bifocal contact lenses are indicated for the correction of refractive ametropia in not-aphakic persons with non-diseased eyes that are nearsighted (myopic), farsighted (hyperopic), and may exhibit corneal astigmatism up to 4.00 diopters that does not interfere with visual acuity. HDS HI 1.54™ toric contact lenses are indicated to correct astigmatism of up to 6.00 diopters.
HDS HI 1.54™ bifocal lenses are indicated to treat presbyopia up to +4.00 D add power.
HDS HI 1.54™ contact lenses are indicated for management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty, radial keratotomy, or LASIK surgery, in otherwise non-diseased eyes.
{2}------------------------------------------------
| Property | HDS HI 1.54Un-irradiated | HDS HI 1.54Irradiated | FluoroPerm 30 |
|---|---|---|---|
| Specific Gravity | 1.12 | - | 1.14 |
| Refractive Index | 1.54 | 1.54 | 1.466 |
| % Light Transmittance* | 93 | 94 | 94 |
| % Water Content | 1 | 1 | <1 |
| OxygenPermeability(Dk)** | 22 | 22 | 30 |
| Hardness (Shore D) | 84 | 84 | 84 |
| Modulus, kgf/cm² | 16,990 | 19,000 | 16,660 |
| Flexure Stress, kgf/cm² | 559 | 700 | 505 |
| Flexure Strain, % | 4 | 5 | 4 |
| Toughness, gf-mm | 429 | 560 | 440 |
| Preservative Uptake,µg/ cm² | CDG 0.35PAPBG 0.01 | - | CDG 0.80PAPBG 0.01 |
| Preservative Release,µg/ cm² | CDG 0.02PAPBG 0.01 | - | CDG 0.05PAPBG 0.01 |
| Soxhlet Extractables, wt%,Hexane / Water | 3.87 / 0.66 | 3.44/0.66 | 3.45 / 0.10 |
| Residuals, wt, %,Acetonitrile, VC-VP | 2.67-0.72 | 2.36-0.15 | - |
| Wetting AngleReceding*/Sessile Drop* | 44/77 | - | 13/68 |
The above indication for use is identical to that of the predicate device except for replacement of visual acuity with refractive ametropia as requested.
*Blue tinted material; Power = plano, Center Thickness = 0.15 ± 0.02 mm
**(cm2/sec) (mL O2) / (mL x mm Hg) ISO/ANSI Method, ISO 9913-1
T Adapted: A New Method for Wetting Angle Measurement; Madigan, et. al., International Eyecare, 01/1998, vol. 2, no 1, p. 45
- ANSI Z80.20-1998 (8.11.1 - 8.11.1.4)
Summary of Non clinical test results
In addition to the non-clinical tests indicated by the table above, studies were performed on the saline extractives following the method of the USP <88> BIOLOGICAL REACTIVITY TEST and toxicological procedures for Ocular Irritation, Systemic Toxicity and Cytotoxicity (ISO 10993-10, ISO 10993-11). These studies found the saline extractives to be small and in line with the predicate material and no indications of toxicity nor irritation were observed in the procedures.
Summary of clinical results
Seventy six (76) subjects (152 eyes) were enrolled and dispensed in the multisite, randomized, double masked clinical study to provide data that support the presumption of equivalence of the HDS HI 1.54™ investigational
{3}------------------------------------------------
lenses to a historical control contact lens. Sixty four (64) subjects (84.2%) completed the study and 12 subjects (15.8%) were discontinued. The population demographics were similar to previous contact lens studies.
Of the ten Test subjects who discontinued, Difficulty Cleaning Lenses (3 subjects) and Poor Comfort (2 subjects), Poor Vision (1 subject) and Poor Comfort (2 subjects) accounted for 80% of the discontinuations. Two Control subjects discontinued, one for Loss of Interest and one for Poor Comfort
There were no adverse events reported during the study. The only study related complications were slit lamp findings of grade 3 for injection. Each of these resolved without complication.
Slit lamp findings were reported at frequencies within expected values and the positive slit lamp observations were primarily grade 1 (trace). Staining and injection were reported most frequently. Subject reports of no symptoms were lowest at the 1 week visit for both the Completed Test and Control eyes and then increased over the remainder of the study. Discomfort was reported most frequently (13.7% of Completed Test eye visits and 12.3% of Completed Control Eye visits). .
Lens comfort was rated as an average of 4.04 (very good) for the Completed Test eyes and 4.07 (very good) for the Completed Control eyes. This compared to a baseline value of 3.96 for the Test eyes and 4.23 for the Control eyes with the pre-study habitual correction.
Keratometry changes were within 1.00 diopter for 93.1% of the Completed Test eyes and 96.4% of the Completed Control eyes. Manifest refraction changes were within 1.00 diopter for 97.9% of the Completed Test eyes and 98.2% of the Completed Control eyes.
One eye of the 63 Completed Test eyes targeted for full distance vision was reported to show a decrease in contact lens visual acuity from the baseline best corrected visual acuity of greater than 0.20 logMAR. The reason for the loss was a reported baseline measurement error. One eye of the 48 Completed Control eyes targeted for full distance vision was reported to show a decrease in contact lens visual acuity from the baseline best corrected visual acuity of greater than 0.20 logMAR. The reason cited for the decrease was lenses being switched eye for eye.
Average lens wearing time was stable at over 13 hours per day for the Completed Test and Control subjects and showed a decrease over time for the discontinued eyes.
Forty nine (49) lens replacements were made for 40 of the 152 eyes dispensed in the study. The replacements were predominantly for deposits (8) or parameter and power change (21) which together account for 59% of the lens replacements. Discomfort was cited for 18.4% (5 test and 4 control lenses) of the lens replacements. Five lenses (10%) were replaced due to loss.
The results of the clinical evaluation of the Paragon HDS HI 1.54™ contact lenses provide evidence of substantial equivalence to the historical control, Paragon Fluroperm® 30 contact leuses.
Conclusions drawn from studies
The conclusions drawn from the nonclinical and clinical tests (discussed above) are that the device is as safe, as effective, and performs as well as or better than the predicate device .
{4}------------------------------------------------
Appendix Two
Indications for Use Form
:
:
.
:
:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.
.
:
: 上一篇:
. . . . .
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with three wings, representing the three levels of government: federal, state, and local. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN 2-7 2009
Paragon Vision Sciences William E. Meyers, Ph.D. Vice President, Science and Technology 945 East Impala Ave. Mesa AZ 85204
Re: K082799
Trade/Device Name: HDS HI 1.54 (pahrifocon A) Rigid Gas Permeable Contact Lens for daily wear
Regulation Number: 21 CFR 886.5916 Regulation Name: Rigid gas permeable contact lens Regulatory Class: II Product Code: HOD Dated: January 19, 2009 Received: January 21, 2008
Dear Dr. Meyers:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{6}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Madina B. Eylands. and
Malvina B. Eydelman, M.D Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
Indications Statement
510(k) Number : K082799
Device Name: HDS HI 154
Indications For Use:
HDS HI 1.54™ rigid gas permeable contact lenses are indicated for daily wear as recommended by the eye care practitioner.
HDS HI 1.54™ rigid gas permeable spheric and bifocal contact lenses are indicated for the correction of refractive ametropia in not-aphakic persons with non-diseased eyes that are nearsighted (myopic), farsighted (hyperopic), and may exhibit corneal astigmatism up to 4.00 diopters that does not interfere with visual acuity. HDS HI 1.54™ toric contact lenses are indicated to correct astigmatism of up to 6.00 diopters.
HDS HI 1.54™ bifocal lenses are indicated to treat presbyopia up to +4.00 D add power.
HDS HI 1.54™ contact lenses are indicated for management of irregular corneal conditions such as keratoconus, THDO 111 1.54 - ochaov rentoo or following penetrating keratoplasty, radial keratotomy, or LASIK surgery, in otherwise non-diseased eyes.
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use X
Over-The Counter Use
Signature
OR
(Optional Format 1-2-96)
Division Sign-Off) Division of Ophthalmie and Ear, Nose and Throat Devices
510(k) Number K082799
§ 886.5916 Rigid gas permeable contact lens.
(a)
Identification. A rigid gas permeable contact lens is a device intended to be worn directly against the cornea of the eye to correct vision conditions. The device is made of various materials, such as cellulose acetate butyrate, polyacrylate-silicone, or silicone elastomers, whose main polymer molecules generally do not absorb or attract water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.